This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SOUTH SAN FRANCISCO, Calif.,
Sept. 18, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq:KBIO) today announced the publication of Phase 1 study results for KB001, a first generation, anti-
Pseudomonas aeruginosa (
Pa) type III secretion system (TTSS) antibody, for use in patients with cystic fibrosis (CF). Data from this initial single dose clinical study supports the continuation of KaloBios' ongoing Phase 2 study of KB001-A, a second generation, anti-TTSS antibody in CF patients with chronic
The Phase 1 study results appear online in the journal
Pediatric Pulmonology, authored by
Carlos Milla, M.D., of the Center for Excellence in Pulmonary Biology,
Stanford University, and other members of the KB001 Study Group.
"Many patients with CF are chronically infected with
Pa which contributes to disease progression by causing a strong inflammatory response that destroys lung tissue," said
Nestor A. Molfino, M.D., M.Sc, KaloBios Chief Medical Officer. "Treating
Pa infection with antibiotics has long been shown to benefit CF patients; however,
Pa is not eradicated by such treatments and antibiotic-resistant strains soon emerge. KB001-A is a novel, non-antibiotic agent against
Pa that targets and inhibits the bacterium's TTSS that is responsible for
Pa's virulence and pro-inflammatory effects.
"The safety, pharmacokinetic and pharmacodynamic results obtained for KB001 in this initial single-dose Phase 1 clinical study supports the continuation of the Phase 2 study currently underway of KB001-A as a potential non-antibiotic treatment to reduce airway inflammation and tissue damage in CF patients with chronic
Pa infection," Dr. Molfino concluded.
The published study results showed a single intravenous dose of KB001 to have an acceptable safety profile and a trend toward a short-term reduction in markers of inflammation, particularly neutrophil elastase which has long been recognized as the main enzyme responsible for lung damage in CF patients. The investigators concluded that repeat-dosing studies are required to evaluate the durability of the anti-inflammatory effects and how treatment with KB001 might translate into clinical benefit.